TESARO (TSRO) Nearly Doubles as Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
Tweet Send to a Friend
TESARO (NASDAQ: TSRO) is surging 88% in pre-open trade after the company announced that the Phase 3 NOVA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE